Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia

Bone Marrow Transplantation

Volumn 29, Issue 10, 2002, Pages 817-823

  Doney, K C ^a   Chauncey, T ^a   Applebaum, F R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic transplantation; Chronic lymphocytic leukemia; Conditioning regimen

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; TRIMETREXATE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; BONE MARROW CELL; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LEUKEMIA CELL; MALE; MONOZYGOTIC TWINS; MYCOSIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; SIBLING; SPLENECTOMY; TREATMENT OUTCOME; VARICELLA ZOSTER VIRUS; VEIN OCCLUSION; WHOLE BODY RADIATION; ACUTE DISEASE; ALLOTRANSPLANTATION; CHRONIC DISEASE; DISEASE FREE SURVIVAL; ISOGRAFT; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGE; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; WHOLE-BODY IRRADIATION; HUMANS; MIDDLE AGED;

EID: 0035998355     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703548     Document Type: Article

References (34)

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
2. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
3. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
4. Rituximab dose-escalation trial in chronic lymphocytic leukemia
5. A critical analysis of staging in CLL
6. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
7. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
8. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group
9. Analysis of amplified variable number tandem repeat loci for evaluation of engraftment after hematopoietic stem cell transplantation
10. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
11. H genes are associated with a more aggressive form of chronic lymphocytic leukemia
12. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors
13. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
14. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
15. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: Preliminary experience in standard treatment resistant patients
16. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
17. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study
18. Nonparametric estimation from incomplete observations
19. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma
20. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
21. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
22. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
23. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: Possible role of graft-versus-leukemia
24. Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia
25. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia
26. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results
27. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia
28. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia
29. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia
30. Hematopoietic stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL)
31. Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): Results and prognostic factors for survival after transplantation. Analysis from EBMT registry
32. Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): The EBMT experience
33. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
34. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects